Advanced search
Start date

Analysis of EGFR and HER2 expression in cervical carcinoma

Grant number: 16/06458-7
Support Opportunities:Scholarships in Brazil - Scientific Initiation
Effective date (Start): July 01, 2016
Effective date (End): December 31, 2016
Field of knowledge:Health Sciences - Medicine - Maternal and Child Health
Principal Investigator:José Humberto Tavares Guerreiro Fregnani
Grantee:Luciana Barreto Silva
Host Institution: Hospital do Câncer de Barretos. Fundação Pio XII (FP). Barretos , SP, Brazil


Cervical cancer is a preventable disease by the detection of cervical precursor lesions, in order to reduce the incidence and mortality and improving the quality of life of these women. Even with all advances in diagnosis and therapies, advanced stage cervical cancer continues to be a challenge and have poor prognosis and high mortality rates. Aims: This study aims to evaluate potential therapeutic proteins EGFR and HER2 that are possible target inhibitors of oncogenic pathways, resulting in promising perspectives in the treatment of this disease. Methods: This is a study with retrospective collection of data from women who had cervical carcinoma and underwent radical hysterectomy in Barretos Cancer Hospital (Stage IB and IIA). TMA (tissue microarray) technique will be used to check the protein expression of EGFR and HER2 in the primary tumor (antibodies: anti-EGFR, 1:500, Dako; anti-HER2, 1:800, Ventana). Protein expressions will be correlated with clinical stage and pelvic lymph node metastasis. Fisher's exact test or chi-square test will be employed in order to make those analyses.

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items

Please report errors in scientific publications list using this form.